TVM is a leading international venture capital firm focused on investing
in life science innovations. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC), that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.
TVM actively invests in lasting partnerships providing portfolio companies with what they each need to succeed: recruiting new management and board members, honing development plans and product registration strategies, finding potential partners and carrying out financing and exit strategies. The TVM global network of entrepreneurs provides management resources, key opinion leaders and everyday contact partners and experts for all relevant specialist areas.